Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alcon Inc | NYSE:ALC | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.09% | 85.58 | 1,925 | 14:05:23 |
From Nov 2023 to Nov 2024
By Denny Jacob
Alcon reported topline results from two trials evaluating AR-15512, a candidate treatment for dry-eye disease.
The eye-care company said the primary endpoint achieved statistical significance in both trials. Additional data derived from secondary endpoints demonstrated the rapid onset and sustained tear production, said Alcon.
AR-15512 was well tolerated and no serious ocular adverse events were reported.
Alcon expects to file a new drug application for AR-15512 with the U.S. Food and Drug Administration in mid-2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 09, 2024 17:05 ET (22:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Alcon Chart |
1 Month Alcon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
